Cargando…

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation

BACKGROUND AND OBJECTIVE: Progressive pulmonary fibrosis is the main cause of death in patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) and in those with idiopathic pulmonary fibrosis (IPF). Transforming growth factor-β (TGF-β) and NADPH oxidase- (NOX-) derived reactive ox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stock, Carmel J. W., Michaeloudes, Charalambos, Leoni, Patricia, Durham, Andrew L., Mumby, Sharon, Wells, Athol U., Chung, Kian Fan, Adcock, Ian M., Renzoni, Elisabetta A., Lindahl, Gisela E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500679/ https://www.ncbi.nlm.nih.gov/pubmed/31119153 http://dx.doi.org/10.1155/2019/1484736

Ejemplares similares

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation
por: Colardo, Mayra, et al.
Publicado: (2023)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy
por: Gargano, Deborah, et al.
Publicado: (2023)

The Role of Bromodomain and Extraterminal (BET) Proteins in Controlling the Phagocytic Activity of Microglia In Vitro: Relevance to Alzheimer’s Disease
por: Matuszewska, Marta, et al.
Publicado: (2022)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma
por: Vichaikul, Sirapa, et al.
Publicado: (2022)

Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter‐balanced by a strong Th2 bias
por: Dalloul, Zeinab, et al.
Publicado: (2021)

Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
por: Morgado-Pascual, Jose Luis, et al.
Publicado: (2019)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

BET Bromodomains Regulate Transforming Growth Factor-β-induced Proliferation and Cytokine Release in Asthmatic Airway Smooth Muscle
por: Perry, Mark M., et al.
Publicado: (2015)

Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2
por: Doherty, Joanne, et al.
Publicado: (2022)

Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration
por: Liu, Chen, et al.
Publicado: (2019)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Wang, Qianqian, et al.
Publicado: (2017)

Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
por: Chen, Ye, et al.
Publicado: (2019)

Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours
por: Mu, Jianfeng, et al.
Publicado: (2020)

The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats
por: Piquereau, Jérôme, et al.
Publicado: (2019)

Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps
por: Keck, Kristin M., et al.
Publicado: (2017)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013)

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
por: Fu, Lei-lei, et al.
Publicado: (2015)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Double-bromo and extraterminal (BET) domain proteins regulate dendrite morphology and mechanosensory function
por: Bagley, Joshua A., et al.
Publicado: (2014)

The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells
por: Pan, Hanyu, et al.
Publicado: (2017)

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
por: Tang, Yujie, et al.
Publicado: (2014)

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma
por: Hensel, Tim, et al.
Publicado: (2015)

Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition
por: Runcie, A. C., et al.
Publicado: (2018)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
por: Funck-Brentano, Elisa, et al.
Publicado: (2020)

Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains
por: Nakagawa, Akifumi, et al.
Publicado: (2016)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Kandela, Irawati, et al.
Publicado: (2015)

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2017)

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
por: Song, Shumei, et al.
Publicado: (2020)

Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)
por: Chang Muñoz, Meilen, et al.
Publicado: (2020)

Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis
por: Bernau, Ksenija, et al.
Publicado: (2022)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5rsj2krtre8n4cadal5lltr5j4